Exagen enters $50M ATM equity offering with Cowen and Company

EXAGEN INC.

Agreement allows Exagen to sell up to $50M of common stock at market prices via Cowen as agent.
Cowen receives 3% commission on gross proceeds; Company not obligated to sell any shares.
Offering terminates upon sale of all shares or termination of the agreement.
Shares sold through Nasdaq Global Market; prospectus supplement filed September 15, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.